SMT202100152T1 - Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab - Google Patents

Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Info

Publication number
SMT202100152T1
SMT202100152T1 SM20210152T SMT202100152T SMT202100152T1 SM T202100152 T1 SMT202100152 T1 SM T202100152T1 SM 20210152 T SM20210152 T SM 20210152T SM T202100152 T SMT202100152 T SM T202100152T SM T202100152 T1 SMT202100152 T1 SM T202100152T1
Authority
SM
San Marino
Prior art keywords
benralizumab
asthmatics
methods
expiratory volume
forced expiratory
Prior art date
Application number
SM20210152T
Other languages
English (en)
Italian (it)
Inventor
Bing Wang
Christine Ward
Lorin Roskos
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT202100152T1 publication Critical patent/SMT202100152T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
SM20210152T 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab SMT202100152T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
EP19158446.5A EP3520811B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (1)

Publication Number Publication Date
SMT202100152T1 true SMT202100152T1 (it) 2021-05-07

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20210152T SMT202100152T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
SM20190311T SMT201900311T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20190311T SMT201900311T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3520811B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN111588849A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2733602T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE053627T2 (https=)
LT (2) LT3033104T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3033104T3 (https=)
PT (2) PT3033104T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT202100152T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306956B2 (en) 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Il-5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
MX376656B (es) * 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
RU2578468C2 (ru) * 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
AU2014306956B2 (en) 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab

Also Published As

Publication number Publication date
WO2015023507A8 (en) 2015-09-24
PL3033104T3 (pl) 2019-09-30
CN105451769A (zh) 2016-03-30
RU2016108809A3 (https=) 2018-06-18
LT3033104T (lt) 2019-06-25
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
JP2020125304A (ja) 2020-08-20
JP2016527325A (ja) 2016-09-08
ME03403B (me) 2020-01-20
CN111588849A (zh) 2020-08-28
HK1225300A1 (en) 2017-09-08
JP2022120010A (ja) 2022-08-17
BR112016002317A2 (pt) 2017-12-12
LT3520811T (lt) 2021-03-25
RS58711B1 (sr) 2019-06-28
SI3520811T1 (sl) 2021-04-30
PL3520811T3 (pl) 2021-08-02
DK3520811T3 (da) 2021-03-22
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
TR201907907T4 (tr) 2019-06-21
HRP20190920T1 (hr) 2019-07-12
JP6746496B2 (ja) 2020-08-26
SMT201900311T1 (it) 2019-07-11
EP3033104A2 (en) 2016-06-22
EP3875487A1 (en) 2021-09-08
EP4579236A3 (en) 2025-09-17
EP3520811A1 (en) 2019-08-07
US9441046B2 (en) 2016-09-13
HK1222559A1 (zh) 2017-07-07
HUE053627T2 (hu) 2021-07-28
KR102337599B1 (ko) 2021-12-10
BR112016002317A8 (pt) 2018-06-12
CY1124399T1 (el) 2022-07-22
EP3033104A4 (en) 2017-03-22
EP4636400A3 (en) 2025-12-24
EP3033104B1 (en) 2019-04-03
SI3033104T1 (sl) 2019-06-28
ES2866426T3 (es) 2021-10-19
PT3033104T (pt) 2019-06-27
MX2016001384A (es) 2016-08-03
US20150044203A1 (en) 2015-02-12
AU2020201277A1 (en) 2020-03-12
ES2733602T3 (es) 2019-12-02
RU2703568C2 (ru) 2019-10-21
CY1122033T1 (el) 2020-10-14
CA2917603C (en) 2023-05-16
CA2917603A1 (en) 2015-02-19
RS61565B1 (sr) 2021-04-29
EP4636400A2 (en) 2025-10-22
KR20160043049A (ko) 2016-04-20
DK3033104T3 (da) 2019-06-17
WO2015023507A2 (en) 2015-02-19
AU2014306959A1 (en) 2016-02-04
EP3520811B1 (en) 2020-12-30
HRP20210406T1 (hr) 2021-04-30
MX381102B (es) 2025-03-12
MX2021003826A (es) 2021-05-27
SG11201600483QA (en) 2016-02-26
EP4579236A2 (en) 2025-07-02
JP2024129140A (ja) 2024-09-26
PT3520811T (pt) 2021-03-15

Similar Documents

Publication Publication Date Title
IL281275B (en) Methods useful in the synthesis of helichondrin b analogs
SMT202100152T1 (it) Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
PL2922052T3 (pl) Sposób ustalania trybu kodowania
IL245524A0 (en) New methods for the production of active tert
PL2950633T3 (pl) Sposoby indukowania tolerancji na suszę w uprawach
GB201321337D0 (en) Improvements in or relating to stairlifts
GB201304101D0 (en) Improvements in or relating to street furniture
SG11201509450QA (en) Methods to produce particles comprising therapeutic proteins
GB201316208D0 (en) Improvements in or relating to optimisation techniques
GB2522975B (en) Improvements to handle assemblies
GB201310608D0 (en) Improvements in or relating to furniture
FI20135228L (fi) Monikäyttötuoli
GB201313010D0 (en) Improvements in or relating to posts
GB2518834B (en) Improvements in or relating to stairlifts
GB201308430D0 (en) Improvements in or relating to replaceable lamps
GB201322789D0 (en) Purge in model
TH1501000545A (th) ยางธรรมชาติที่มีนาโนคาร์บอน (Natural rubber containing nanocarbon)
GB201315798D0 (en) Improvements in or relating to storage
GB201315795D0 (en) Improvements in or relating to storage
GB201315797D0 (en) Improvements in or relating to storage
GB201303688D0 (en) Improvements in or relating to stairlifts
GB201306136D0 (en) Improvements in or relating to storage
GB201306134D0 (en) Improvements in or relating to storage
FI20120373L (fi) Opiskelu- ja työtuoli
FI9766U1 (fi) Tilavuudeltaan säädettävä kovakuorinen lompakko